Liu, Joyce F <br/><br/>
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.  [electronic resource] 

 -  The Lancet. Oncology  Oct 2014 
 - 1207-14 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(14)70391-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Ovarian Epithelial<br/>Cisplatin--administration & dosage<br/>Confidence Intervals<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Kaplan-Meier Estimate<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Phthalazines--administration & dosage<br/>Piperazines--administration & dosage<br/>Quinazolines--administration & dosage<br/>Risk Assessment<br/>Survival Analysis<br/>Treatment Outcome